Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything

Journal of Hepatology

Volumn 68, Issue 1, 2018, Pages 217-218

  Mazzarelli, Chiara ^a,b   Cannon, Mary D ^a   Belli, Luca S ^b   Agarwal, Kosh ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Hepatology Unit and Gastroenterology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL AGENT; PROTEINASE INHIBITOR; SOFOSBUVIR; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; CANCER PATIENT; CANCER THERAPY; GENOTYPE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LETTER; LIVER CANCER; LIVER RESECTION; LIVER TRANSPLANTATION; PRIORITY JOURNAL;

EID: 85031710919     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.08.025     Document Type: Letter

References (10)

1. Beste, L.A., Green, P.K., Berry, K., et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol 67 (2017), 32–39.
2. Prenner, S., VanWagner, L.B., Flamm, S.L., et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol 66 (2017), 1173–1181.
3. Dailey, F., Ayoub, W., Hepatitis C virus therapy for decompensated and posttransplant patients. J Clin Gastroenterol 51 (2017), 215–222.
4. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66 (2017), 153–194.
5. Terrault, N.A., McCaughan, G.W., Curry, M.P., et al. International liver transplantation society consensus statement on hepatitis C management in liver transplant candidates. Transplantation 101 (2017), 945–955.
6. Belli, L.S., Duvoux, C., Berenguer, M., et al. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol 67 (2017), 585–602.
7. Jakobsen, J.C., Nielsen, E.E., Feinberg, J., et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev, 2017, 10.1002/14651858.CD012143.pub2.
8. Bruno, S., Di Marco, V., Iavarone, M., et al. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. Liver Int, 2017, 10.1111/liv.13452.
9. Reig, M., Mariño, Z., Perelló, C., et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65 (2016), 719–726.
10. Cammà, C., Cabibbo, G., Craxì, A., Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. J Hepatol 65 (2016), 861–862.